TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02285543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPF induction chemotherapy
Description: TPF induction chemotherapy: 2 cycles; docetaxel(75mg/m\^2), cisplatin(75 mg/m\^2), 5-Fu(750 mg/m\^2/day) for 5 days; 16 days later, the 2nd cycle. 2 weeks later, surgery.~Surgery: radical resection and full neck dissection with reconstruction. Radiotherapy: 4-6 weeks after surgery, 1.8-2Gy/day, 5 days/week for 6 weeks, and totally 54-60Gy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: surgery
Description: In the TPF group,surgery was performed at least 2 weeks after completion of induction chemotherapy.Surgery group includes radical resection of the primary lesion and full neck dissection(functional or radical) with proper reconstruction(pedicle or free flap) were performed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Description: In the TPF group,surgery was performed at least 2 weeks after completion of induction chemotherapy.Surgery group includes radical resection of the primary lesion and full neck dissection(functional or radical) with proper reconstruction(pedicle or free flap) were performed.

Intervention type: RADIATION
Group type: OTHER
Intervention: radiotherapy
Description: Radiotherapy was arranged 4 to 6 weeks after surgery.Routine external beam radiotherapy, such as conformal or intensity modulated radiotherapy was performed, and the dose was 1.8-2 Gy(gray)/day, 5 days/week for 6 weeks, and totally 54-60 Gy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: Radiotherapy was arranged 4 to 6 weeks after surgery.Routine external beam radiotherapy, such as conformal or intensity modulated radiotherapy was performed, and the dose was 1.8-2 Gy(gray)/day, 5 days/week for 6 weeks, and totally 54-60 Gy.
Study: NCT01615211

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Day 1 Letrozole 2,5mg 3 tablets Day 2 Letrozole 2,5mg 3 tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trilostane
Description: Day 1 Trilostane 120mg twice and Day 2 Trilostane 240mg twice
Study: NCT01439022

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Programme
Description: 6 months 2 x a week aerobic and anaerobic exercise delivered in community facilities by an exercise professional and supported by a physiotherapist

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hand Writing programme
Description: 6 months 2 x a week hand writing practice. Performed in the home supported by a physiotherapist (5 support sessions)
Study: NCT01067261

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous mechanical nerve stimulation (TMNS)
Description: Device: Transcutaneous mechanical nerve stimulation by A medical vibrator (FERTI CARE personel, Multicept A/S, Albertslund, Danmark)~A medical vibrator (FERTI CARE personel, Multicept A/S, Albertslund, Denmark) will be used. The stimulation works through a vibrating disc of hard plastic with a diameter of 3.5 cm. The stimulation point will be the frenulum. A stimulation sequence consisting of 10 seconds of stimulation followed by a 10 second pause repeated 10 times will be used. The treatment will be initiated 1 to 4 weeks before the radical prostatectomy and re-initiated 0 to 14 days after the operation. The treatment will then continue for 6 weeks. The stimulation will be preformed daily by the patients in their own homes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor muscle training
Description: Regular pelvic floor training which is offered to all patients undergoing a radical prostatectomy at Herlev Hospital.
Study: NCT01886586

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Problem Solving Therapy
Description: 6-12 sessions of Problem Solving Therapy (both members of dyad)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Problem Solving Therapy + Exercise
Description: 6-12 sessions of Problem Solving Therapy + Exercise (both members of dyad)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: Staff will document and monitor all mental health treatment (e.g., medications that participant may be taking) and psychotherapy (e.g. counseling or social services).
Study: NCT04288141

Intervention type: OTHER
Intervention: Acquisition of blood samples and tumour tissue samples (biopsies)
Description: Acquisition of blood samples and tumour tissue samples (biopsies) in a sequential manner as participants proceed through HER2-directed therapy as prescribed by their oncologist.

Intervention type: OTHER
Intervention: Acquisition of blood samples and tumour tissue samples (biopsies)
Description: Acquisition of blood samples and tumour tissue samples (biopsies) in a sequential manner as participants proceed through HER2-directed therapy as prescribed by their oncologist.
Study: NCT03688958

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Selected patients with early breast cancer (stage II) non-pretreated received colored water solution (placebo) within the time before the hospital assigned them to her surgery (7 to 35 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iodine
Description: Selected patients with early breast cancer (stage II) non-pretreated received iodine solution (Experimental) within the time before the hospital assigned them to her surgery (7 to 35 days).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: FEC/TE Placebo
Description: The selected patients with advanced breast cancer (stage III) non-pretreated received colored water solution (placebo) within the time of oncology designed chemotherapy treatment FEC/TE (4 or 6 cycles/ every 21 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FEC/TE iodine
Description: The selected patients with advanced breast cancer (stage III) non-pretreated received iodine solution (experimental) within the time of oncology designed chemotherapy treatment (4 or 6 cycles/ every 21 days).
Study: NCT06237244

Intervention type: DIAGNOSTIC_TEST
Intervention: triglyceride to glucose ratio
Description: Ratio of triglyceride level to glucose

Intervention type: DIAGNOSTIC_TEST
Intervention: triglyceride to glucose ratio
Description: Ratio of triglyceride level to glucose

Intervention type: DIAGNOSTIC_TEST
Intervention: triglycerdie to HDL ratio
Description: Ratio of triglyceride to HDL cholesterol

Intervention type: DIAGNOSTIC_TEST
Intervention: triglycerdie to HDL ratio
Description: Ratio of triglyceride to HDL cholesterol
Study: NCT01740128

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic body weight supported treadmill training
Description: 30-minute sessions will be conducted 3-4 times per week for a total of 48 sessions over 12 to 16 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Robotic body weight supported treadmill training
Description: 30-minute sessions will be conducted 3-4 times per week for a total of 48 sessions over 12 to 16 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Harness-supported multimodal balance training
Description: 30-minute sessions will be conducted 3-4 times per week for a total of 48 sessions over 12 to 16 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Harness-supported multimodal balance training
Description: 30-minute sessions will be conducted 3-4 times per week for a total of 48 sessions over 12 to 16 weeks.
Study: NCT01950117

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic mucosal resection
Description: Nonpedunculated neoplastic colorectal polyps from 10 mm to 25 mm in diameter were resected after submucosal injection of saline solution before removal.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional polypectomy
Description: Nonpedunculated neoplastic colorectal polyps from 10 mm to 25 mm in diameter were resected using conventional polypectomy. Submucosal injection of saline solution before removal was not performed.
Study: NCT03161314

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conservative physical therapy treatment with strengthening exercise program, and Conservative physical therapy treatment with stretching exercise program
Description: (Sub-project 3) conservative physical therapy treatment with self-strengthening and with self-stretching home based exercises

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conservative physical therapy treatment with strengthening exercise program, and Conservative physical therapy treatment with stretching exercise program
Description: (Sub-project 3) conservative physical therapy treatment with self-strengthening and with self-stretching home based exercises
Study: NCT01448720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate
Description: Type=exact number, unit=mg, number=150, 100, 75 mg equivalent (eq), form=suspension for injection, route=intramuscular use. One IM injection of 150 mq on Day 1, 100 mg eq. on Day 8 (+/- 4 days), and 75 mg eq. is recommended on Days 36, 64, and 92.
Study: NCT00504296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDAC inhibitor SB939
Description: SB939 will be administered initially for 3 consecutive days every other week at the first dose level and then for 5 consecutive days every other week at escalating doses.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunoenzyme technique

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunologic technique

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: liquid chromatography

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mass spectrometry

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Study: NCT00334867

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexrazoxane hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexrazoxane hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ifosfamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional surgery
Description: Patients undergo surgery in week 18

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: Patients undergo surgery in week 18

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: Patients undergo radiation therapy in week 19

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Patients undergo radiation therapy in week 19
Study: NCT01128777

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nondirective supportive group therapy
Description: Patient initiated discussions form the basis for the intervention for both the adolescent group and the parent group
Study: NCT00664820

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic capsules containing Lactobacillus rhamnosus GR-1 and L. reuteri RC-14
Description: 2 capsules daily for 3 months.
Study: NCT02996097

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Lutronic electronic carbon dioxide (eCO2) Plus laser system
Description: CO2 ablative laser plus intralesional triamcinolone acetonide A topical EMLA cream or tetracaine 7%/lidocaine 23% will be applied to the both treatment sites and after sufficient anesthesia is attained, one keloid will be treated with the fractional CO2 laser using standard protocol as practiced in our clinics followed by intralesional triamcinolone acetonide. One lesion would be treated with fractional CO2 ablative laser followed with intralesional triamcinolone acetonide at 4 weeks intervals

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intralesional Triamcinolone Acetonide
Study: NCT02979626

Intervention type: PROCEDURE
Intervention: Respiratory nasal swab
Description: Nasal swabs will be obtained for testing by the study nurses. If a respiratory sample has already been collected as part of routine clinical care, this will replace the study collection, and no additional testing will be required.
Study: NCT02996097

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intralesional Triamcinolone Acetonide
Study: NCT03412513

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirabegron
Description: Mirabegron 50mg po daily for 12 weeks to Active Comparator group, and 4 weeks(from visit 4 to visit 5) to Placebo comparator group.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo po daily for 8 weeks to Placebo comparator group.
Study: NCT00510783

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Keppra
Description: The patient will receive 1 gram of Keppra added to 100ml diluent and will be infused over 15 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosphenytoin
Description: IV load will be dependant on dilantin level. If no dilantin is detected in the patient, the patient will receive 1 gram of IV Fosphenytoin infused at 15 mg/min or slower depending on vitals.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dilantin
Description: IV load will be dependant on dilantin level. If no dilantin is detected in the patient, the patient will receive 1 gram of IV phenytoin infused at 25 mg/min or slower depending on vitals.
Study: NCT03710070

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Amplatzer vascular plug 4
Description: See above
Study: NCT01625949

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intracoronary stem cells injection
Description: Intracoronary stem cells will be injected in the infarct related artery after a successful coronary dilatation and stenting autologous bone marrow stem cells from iliac crest 60 ml bone marrow will be extracted and purified for mononuclear cells which will be injected.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: coronary dilatation and stenting
Description: coronary dilatation and stenting
Study: NCT03263234

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 8 weeks of circadian adjusted LED-based lighting (CALED)
Description: The luminaires are installed before the beginning of either the control or the intervention period. During the control period (8 weeks) the luminaires have normal light. During the intervention period (8 weeks) the luminaires have CALED. Cromaviso will calibrate CALED to mimic circadian rhythm according to the latest knowledge about the light phase-response curve for elderly.
Study: NCT01093183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT04017702

Intervention type: DEVICE
Intervention: Expiron respirator
Description: Respiratory volume monitor (RVM) (ExSpiron, is a non-invasive FDA approved device that monitors minute ventilation (MV) and provides an early indication of respiratory status in non-intubated patients. The system consists of a lightweight monitor, a patient cable, and a disposable electrode PadSet, which detects changes in breathing.
Study: NCT03710070

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Control
Description: Angiography of the IMA without occlusion
Study: NCT00504491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab-CHOP-Alemtuzumab
Description: Four Rituximab - CHOP courses will be given The courses will be given every 21 days
Study: NCT01585324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 mcg subcutaneously weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin [Copegus]
Description: 1000 mg or 1200 mg orally daily
Study: NCT01032421

Intervention type: PROCEDURE
Intervention: IVF procedure
Study: NCT01481584

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein drink - protein isolate
Description: The subjects consumed 500 mL of a protein drink (tomato juice) containing 30 g protein (canola protein isolate or reference protein) after overnight fasting. After run-in period, each volunteer have to pass both protein-intervention days in different order with a four-week wash out period in between.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protein drink - protein isolate
Description: The subjects consumed 500 mL of a protein drink (tomato juice) containing 30 g protein (canola protein isolate or reference protein) after overnight fasting. After run-in period, each volunteer have to pass both protein-intervention days in different order with a four-week wash out period in between.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein drink - protein hydrolyzate
Description: The subjects consumed 500 mL of a protein drink (tomato juice) containing 30 g protein (canola protein hydrolyzate or reference protein) after overnight fasting. After run-in period, each volunteer have to pass both protein-intervention days in different order with a four-week wash out period in between.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protein drink - protein hydrolyzate
Description: The subjects consumed 500 mL of a protein drink (tomato juice) containing 30 g protein (canola protein hydrolyzate or reference protein) after overnight fasting. After run-in period, each volunteer have to pass both protein-intervention days in different order with a four-week wash out period in between.
Study: NCT02378415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: IV Bolus dose of ketamine dosed at 0.2mg/kg infused over 1-2 minutes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline Infusion
Study: NCT04855617

Intervention type: DRUG
Intervention: Ocrelizumab
Description: Administer Ocrelizumab under the close supervision of an experienced healthcare professional with access to appropriate medical support to manage severe reactions such as serious infusion reactions.~* Initial dose: 300 mg intravenous infusion, followed two weeks later by a second 300 mg intravenous infusion.~* Subsequent doses: single 600 mg intravenous infusion every 6 months.~* Observe the patient for at least one hour after the completion of the infusion
Study: NCT02987517

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Increased running cadence gait retraining
Description: Runners use an increased cadence, or step rate, 7.5% greater than baseline preferred cadence

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Forefoot Strike gait retraining
Description: Runners use a forefoot strike running gait instead of a rear foot strike running gait.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strengthening exercises
Description: foot and ankle strengthening exercises performed by all subjects to prepare musculoskeletal tissues for requirements of new running gait.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strengthening exercises
Description: foot and ankle strengthening exercises performed by all subjects to prepare musculoskeletal tissues for requirements of new running gait.
Study: NCT01701297

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cotrimoxazole
Description: Cotrimoxazole 960mg orally each day (two 480mg tablets)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VSL#3 active
Description: The prescribed dose was 2 sachets (containing 900 billion bacteria) orally each day for 48 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: VSL#3 placebo
Description: This was two placebo sachets identical to VSL#3 active sachet. The prescribed dose was 2 sachets orally each day for 48 weeks
Study: NCT00005072

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Leuvectin
Description: 1000 ug of Leuvectin injected intratumorally
Study: NCT02983435

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: G1 - Thrust manipulation
Description: Osteopathic manipulation with Thrust technique. The Group 1 (G1) will receive the Thrust technique applied at the level of dysfunction. Subject in lateral decubitus, with one lower limb extended and the other in flexion, to the level of the targeted vertebra; upper trunk rotated back until the same vertebra; at the end of the range of movement will be applied the high speed and low amplitude impulse (Thrust).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: G2 - Muscle Energy
Description: Osteopathic manipulation with Muscle Energy technique. The Group 2 (G2) will receive the Muscle Energy technique applied at the level of dysfunction. Subject in lateral decubitus, with the upper and lower trunk flexed until the target vertebra, and upper trunk rotated back to the level of the same vertebra; lumbar in lateral flexion (using the subject's feet) until the target vertebra. Following the command the subject will perform an isometric contraction of 3-5 seconds against the therapist's hand (pushing the hand towards the floor), repeated 3 times.
Study: NCT02691728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF FDC
Study: NCT01690910

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rifton Gait Trainer

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Front Wheeled Walker
Study: NCT04399408

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Obstetrics Ultrasound (non invasive)
Description: Participants are instructed to preform 1-3 short (3 minuets) ultrasound scans a day according to pre-defined steps.